Middle East Pharmaceutical Industries Company (TADAWUL:4016)
Saudi Arabia · Delayed Price · Currency is SAR 66.85
+0.15 (0.22%)
Sep 3, 2026, 3:10 PM AST
TADAWUL:4016 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 512.08 | 460.48 | 394 | 338.44 | 302.66 | 287.22 | |
Revenue Growth | 18.52% | 16.87% | 16.42% | 11.82% | 5.38% | -4.79% |
Cost of Revenue | 194.26 | 174.71 | 151.59 | 134.74 | 119.21 | 113.47 |
Gross Profit | 317.82 | 285.78 | 242.41 | 203.7 | 183.45 | 173.76 |
Selling, General & Admin | 193.28 | 177.35 | 150 | 127.59 | 113.73 | 97.74 |
Other Operating Expenses | -0.58 | 0.02 | -0.42 | 0.09 | 0.18 | -0.14 |
Operating Expenses | 196.73 | 178.84 | 153.12 | 126.17 | 114.04 | 97.6 |
Operating Income | 121.09 | 106.93 | 89.29 | 77.53 | 69.41 | 76.16 |
Interest Expense | -5.45 | -3.25 | -3.67 | -5.75 | -4.73 | -1.87 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.04 | -0.47 | 0.27 | - |
Other Non Operating Income (Expenses) | - | - | - | - | - | -1.08 |
EBT Excluding Unusual Items | 115.66 | 103.7 | 85.58 | 71.31 | 64.95 | 73.22 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -2.76 |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | 0.12 | 0.13 | 0.08 | - |
Pretax Income | 115.7 | 103.74 | 86.35 | 71.44 | 65.02 | 70.46 |
Income Tax Expense | 7.2 | 6.73 | 6.5 | 5.61 | 5.57 | 4.18 |
Net Income | 108.5 | 97.01 | 79.85 | 65.83 | 59.45 | 66.28 |
Net Income to Common | 108.5 | 97.01 | 79.85 | 65.83 | 59.45 | 66.28 |
Net Income Growth | 16.81% | 21.49% | 21.30% | 10.72% | -10.31% | -8.97% |
Shares Outstanding (Basic) | 35 | 35 | 35 | 35 | 35 | 35 |
Shares Outstanding (Diluted) | 35 | 35 | 35 | 35 | 35 | 35 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 3.10 | 2.77 | 2.28 | 1.88 | 1.70 | 1.89 |
EPS (Diluted) | 3.10 | 2.77 | 2.28 | 1.88 | 1.70 | 1.89 |
EPS Growth | 16.81% | 21.49% | 21.30% | 10.72% | -10.31% | -8.97% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 48.71 | 73.74 | 21.91 | 71.82 | 58.99 | 25.28 |
Free Cash Flow Per Share | 1.39 | 2.11 | 0.63 | 2.05 | 1.69 | 0.72 |
Dividend Per Share | 0.754 | 1.383 | 1.143 | - | - | - |
Dividend Growth | -43.83% | 21.00% | - | - | - | - |
Gross Margin | 62.06% | 62.06% | 61.52% | 60.19% | 60.61% | 60.50% |
Operating Margin | 23.65% | 23.22% | 22.66% | 22.91% | 22.93% | 26.52% |
Profit Margin | 21.19% | 21.07% | 20.27% | 19.45% | 19.64% | 23.08% |
Free Cash Flow Margin | 9.51% | 16.01% | 5.56% | 21.22% | 19.49% | 8.80% |
EBITDA | 130.29 | 119.12 | 99.08 | 85.14 | 76.25 | 82.86 |
EBITDA Margin | 25.44% | 25.87% | 25.15% | 25.16% | 25.19% | 28.85% |
D&A For EBITDA | 9.2 | 12.19 | 9.8 | 7.61 | 6.84 | 6.7 |
EBIT | 121.09 | 106.93 | 89.29 | 77.53 | 69.41 | 76.16 |
EBIT Margin | 23.65% | 23.22% | 22.66% | 22.91% | 22.93% | 26.52% |
Effective Tax Rate | 6.22% | 6.49% | 7.53% | 7.85% | 8.57% | 5.93% |